MyAverix Finance MyAverix Finance

XETRA · Healthcare

NEWRON PHARMACEUT. EO-20 (NP5)

Biotechnology

NEWRON PHARMACEUT. EO-20 (NP5) is listed on XETRA in the Healthcare sector. Industry: Biotechnology. As of 2026-05-24, reported P/E ratio is 25.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Data as of 2026-05-24

Download on the App Store Get it on Google Play

Download free on iPhone and Android

Key metrics for NP5

P/E ratio
25.00

NEWRON PHARMACEUT. EO-20 (NP5) — FAQ

What is NP5's P/E ratio?

The price-to-earnings (P/E) ratio for NEWRON PHARMACEUT. EO-20 (NP5) is 25.00 (data as of 2026-05-24).

Does NEWRON PHARMACEUT. EO-20 pay a dividend?

Dividend yield is not available in the current snapshot for NEWRON PHARMACEUT. EO-20 (NP5). Check the MyAverix Finance app for the latest dividend data.

What sector is NEWRON PHARMACEUT. EO-20 in?

NEWRON PHARMACEUT. EO-20 (NP5) is classified in the Healthcare sector (Biotechnology industry).

What exchange is NP5 listed on?

NP5 is listed on XETRA.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Aimed Bio (0009K0) Celltrion (068270) Rznomics (476830)

← All stocks

MyAverix Finance provides company information and financial data for educational and research purposes only. We are not a broker, advisor, or investment service. Data may be delayed or incomplete. Past performance does not guarantee future results. Always do your own research before making financial decisions.

Terms of Use

App Store Google Play